Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application
Authors:
- Danièle Bentué-FerrerDBDanièle Bentué-Ferrer
- Eric BellissantEBEric Bellissant
- 20 October 2010
- journal article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 49 (1) , 69-75
Abstract
Background: Daptomycin is a recently developed cyclic lipopeptide antibiotic active against most Gram-positive pathogens including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. To optimize treatment efficacy and safety, especially in patients undergoing multiple drug regimens and/or co-morbidities, a specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the quantification of daptomycin in plasma. Methods: A C18 column was used for separation, with a mobile phase initially consisting of 0.1% formic acid, water, and acetonitrile (ACN) in a linear gradient from 20% to 70%. After protein precipitation with ACN, the clear upper layer was diluted in water:ACN (50:50, v/v) before injection. Detection was performed using an electrospray ionization technique. MS/MS transitions, monitored in the positive ion mode were m/z 811.1 → m/z 313.1 for daptomycin, and m/z 609.4 → m/z 194.9 for reserpine, used as internal standard. Results: Elution of daptomycin and reserpine occurred at 4.5 and 3.9 min, respectively. The method was validated over a range of concentrations from 1 mg/L to 120 mg/L. The assay met recommended acceptance criteria: coefficients of variation were Conclusions: This method appears well-adapted to routine hospital practice for therapeutic drug monitoring of daptomycin considering its time of analysis, range of concentrations measured, precision and accuracy.Keywords
This publication has 29 references indexed in Scilit:
- Daptomycin: rationale and role in the management of skin and soft tissue infectionsJournal of Antimicrobial Chemotherapy, 2008
- Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issueJournal of Antimicrobial Chemotherapy, 2008
- Daptomycin: A Review 4 Years after First ApprovalPharmacology, 2007
- DaptomycinJournal of Infection, 2007
- Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002–2004)Clinical Microbiology and Infection, 2006
- Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infectionsJournal of Antimicrobial Chemotherapy, 2005
- Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2003
- Pharmacokinetics and Inflammatory Fluid Penetration of Intravenous Daptomycin in VolunteersAntimicrobial Agents and Chemotherapy, 2002
- Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremiaAntimicrobial Agents and Chemotherapy, 1992
- Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteersAntimicrobial Agents and Chemotherapy, 1992